NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Helix BioPharma Corp. Strengthens Executive Leadership Ahead of U.S. Listing and L-DOS47 Clinical Development
Helix BioPharma announced the appointments of Helen Middleton as General Counsel and David Browning as VP of Clinical Operations to support its planned U.S. listing and the next phase of L-DOS47 clinical development for non-small cell lung cancer.
The appointments strengthen Helix’s executive leadership team to support the Company’s planned U.S. securities exchange listing, advance the next stage of development for L-DOS47 (LDOS007 study in first-line NSCLC), and build the legal, governance and operational infrastructure for its next phase of growth.
Helen Middleton was appointed as General Counsel, bringing over 30 years of experience in pharmacy, law, and life sciences. David Browning was appointed as Vice President of Clinical Operations, with experience leading complex global oncology programs.
L-DOS47 is Helix’s drug candidate for non-small cell lung cancer (NSCLC). The Company is advancing it into the next stage of clinical development with the planned LDOS007 Phase IB/Randomized Phase II study in first-line NSCLC.
The planned U.S. listing is a key part of Helix’s capital markets roadmap. The Company is preparing a base shelf prospectus and has completed auditor review of second-quarter financials to support this transition.
Ms. Middleton has over 30 years of experience as a qualified life sciences lawyer and registered clinical pharmacist. She has held senior legal roles at firms such as Sidley Austin LLP, Matheson LLP, Mundipharma International, Ipsen, and Abcam, and most recently served as Legal Consultant to Kyowa Kirin International.
David Browning holds an MBA and has successfully led complex global oncology programs from planning through execution. His expertise in clinical operations will support the operational excellence required to advance L-DOS47 toward patients.
Helix BioPharma is a clinical-stage oncology company focused on making hard-to-treat cancers vincible, with a current emphasis on developing L-DOS47 for non-small cell lung cancer.